- Home
- MMA vs XCUR Comparison
MMA vs XCUR Comparison
Compare MMA & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | XCUR |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 13.7M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MMA | XCUR |
|---|---|---|
| Price | $0.39 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.6K | ★ 239.4K |
| Earning Date | 05-20-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $1.43 |
| 52 Week High | $2.00 | $9.48 |
Technical Indicators
Market Signals| Indicator | MMA | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 34.94 |
| Support Level | $0.35 | $1.43 |
| Resistance Level | $0.50 | $2.02 |
| Average True Range (ATR) | 0.03 | 0.22 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.09 | 22.31 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.